D015195OccupationsE05.295.500H01.158.703.007.675.500H01.181.466.675.500470.98958Drug Designcmhprofilesont:personsuffixperson suffixFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson12718723Leeder JSPharmacogenomicsLeeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics. 2003 May; 4(3):331-41.Pharmacogenomics2003-05-01T00:00:002003Developmental and pediatric pharmacogenomics.15203092Leeder JSDrug discovery todayLeeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today. 2004 Jul 01; 9(13):567-73.Drug Discov Today2004-07-01T00:00:002004Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond.20150527Leeder JS, Kearns GL, Spielberg SP, van den Anker JJournal of clinical pharmacologyLeeder JS, Kearns GL, Spielberg SP, van den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol. 2010 Dec; 50(12):1377-87.J Clin Pharmacol2010-02-11T00:00:002010Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.0.8564280.02253994research area of0.7339380.06151168subject area forPhD, MScWarrenCheungWarren Cheung0.000000000000000.00000000000000119Cheung, Warren0000-0003-0267-7464Bioinformatics Manager1Professor23819887Cheung WA, Ouellette BF, Wasserman WWBMC medical genomicsCheung WA, Ouellette BF, Wasserman WW. Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity. BMC Med Genomics. 2013; 6 Suppl 2:S3.BMC Med Genomics2013-05-07T00:00:002013Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity.PediatricsResearchClinicalPharmD, PhDJ. StevenLeederJ. Steven Leeder39.08346750000000-94.5771129000000034Leeder, J. Steven0000-0001-6688-0504Deputy Director, Children's Research InstituteChildren's Mercy Kansas CityMDJayPortnoyJay M. Portnoy0.000000000000000.00000000000000205Portnoy, JayMedical Director, Telemedicinetrue1Medical Director, TelemedicineMedical Director, Telemedicinetrue1Bioinformatics ManagerBioinformatics ManagerGenomic Medicine CenterPhDBrookeFridleyBrooke Fridley0.000000000000000.00000000000000222Fridley, BrookeDirector, Biostatistics and Epidemiology Core31594982Abbas-Aghababazadeh F, Lu P, Fridley BLScientific reportsAbbas-Aghababazadeh F, Lu P, Fridley BL. Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines. Sci Rep. 2019 10 08; 9(1):14421.Sci Rep2019-10-08T00:00:002019Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines.true1Director, Biostatistics and Epidemiology CoreDirector, Biostatistics and Epidemiology Coretrue1Deputy Director, Children's Research InstituteDeputy Director, Children's Research Institute